Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of oxyntomodulin methodology for ketogenesis and glucose-dependent insulin secretion in healthy overweight men
NL-OMON35025Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2010
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Randomised trial of oxyntomodulin in obesity (2 arms), sponsored by Merck & Co. Primary endpoints: Pharmacodynamics, Pharmacokinetics and 1 more. Started Apr 2010; status: active, not recruiting.
02
Drugs
oxyntomodulin
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON35025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35025.